on Xlife Sciences AG (isin : CH0461929603)
Strategic Alliance to Boost Korean Life Sciences Ventures' Global Reach
Xlife Sciences AG, a Swiss incubator and accelerator, has signed a strategic Memorandum of Understanding (MoU) with JIPYONG LLC, a Korean law firm, and JIPYONG IP, an intellectual property advisory firm. This partnership aims to enhance the global market access of Korean life sciences ventures by facilitating international capital markets, potential listings, and strengthened global positioning.
The MoU, signed in Seoul, involves initiatives across five strategic pillars, including company evaluation, investment facilitation, capital market advisory, IP strategy, and market intelligence sharing. This collaboration seeks to bolster the global profile of Korean biopharma and medtech companies, leveraging combined expertise for substantial growth.
Oliver R. Baumann, CEO of Xlife Sciences, emphasized the value of integrating incubation expertise with legal and IP strengths to unlock growth opportunities for Korean innovators in the global arena.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Xlife Sciences AG news